Berita Kesehatan
The COVID-19 pandemic and pulmonary arterial hypertension
Rabu, 26 Okt 2022 09:30:57

Claudia Mickael, Michael H. Lee, Brian B. Graham

European Respiratory Journal 2022 60: 2200796; DOI: 10.1183/13993003.00796-2022


The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by widespread infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused immense morbidity and mortality worldwide. While COVID-19 has affected many patients with chronic comorbidities, its potential impact on patients with chronic diseases is of great concern, and particularly those with pulmonary arterial hypertension (PAH), as the viral infection also causes pulmonary vascular pathology [1]. PAH patients are prone to decompensated right heart failure resulting in hospitalisations and even deaths [2], with infections representing a common triggering factor [3]. Furthermore, even patients without underlying PAH can secondarily develop pulmonary hypertension due to acute respiratory distress syndrome (ARDS) [4], and COVID-19-associated ARDS also appears to cause pulmonary hypertension [5–7], which can be long-lasting [8–10].

This editorial summarises the key findings of R. Badagliacca and co-workers regarding the changes in care and clinical outcomes of PAH patients during the initial COVID-19 pandemic in Italy


  • Conflicts of interest: B.B. Graham reports grants from NIH, outside the submitted work. All other authors have nothing further to disclose.

  • Support statement: Funding was provided by Actelion Pharmaceuticals Entelligence Early Investigator award (C. Mickael); and NIH grants P01HL152961 and R01HL135872 (B.B. Graham). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received April 21, 2022.
  • Accepted April 29, 2022.